Director, Precision Medicine Strategy
AstraZeneca
Summary
As Director, Precision Medicine Strategy, you will lead cross-indication strategy and planning for the US Precision Medicine portfolio. Reporting to the Senior Director, Precision Medicine Strategy & Effectiveness, you will own tumor and biomarker strategy, prioritization, and launch readiness, and lead the team supporting biomarker-driven launches and upstream planning.
Job description
Working in close partnership with Franchise Heads, Global Diagnostics, Medical Diagnostics, Access, Insights & Analytics, and the Lab Ecosystem & Diagnostic Partnerships Director, you will translate strategy into lab-readiness priorities and ensure the organization focuses on the highest-value launches.
Key Responsibilities
Strategy & Prioritization
- Lead cross-indication precision medicine strategy and planning for the US portfolio.
- Own tumor and biomarker strategy, portfolio prioritization, and launch readiness for Lung, Breast, GI/Heme, and G2 oncology.
- Anticipate biomarker and testing requirements and recommend investments for the highest-value launches.
Team Leadership
- Lead three tumor-type Sr. Associate Directors (Lung, Breast, and GI/G2/Heme) and the Associate Director, PM Strategy, setting objectives, ensuring consistent launch-readiness plans, and developing talent.
- Establish common planning frameworks and the PM Launch Playbook with the Senior Director.
Lab & Cross-Functional Alignment
- Translate strategy into lab-readiness priorities with the Lab Ecosystem & Diagnostic Partnerships Director.
- Align global and US initiatives, and influence Brand, Medical, Access, and Field leaders through data-driven recommendations.
- Represent PM Strategy in franchise, brand planning, and forecasting forums.
Compliance & Governance
- Ensure all activities are conducted in accordance with AstraZeneca policies, Code of Ethics, SOPs, and applicable regulatory requirements.
- Maintain high standards of scientific integrity, compliance, and patient-centered execution.
Leadership Expectations
- Strategic thinking and a strong commercial mindset.
- Ability to translate complex science into strategy.
- Talent development.
- Launch excellence.
- Passion for advancing precision medicine.
Scope of Responsibility
This role leads PM strategy for all biomarker-driven launches across the US oncology portfolio, including Gold-tier launches.
Requirements
- Bachelor's degree in Life Sciences, Healthcare, Business, Marketing, or related field
- Minimum of 10 years of progressive oncology, precision medicine, and diagnostics experience in pharmaceutical or diagnostics settings
- Leadership of biomarker-driven launches or PM strategy
- Knowledge of companion diagnostics, molecular testing, and adoption barriers
- People leadership experience
- Proven ability to influence in a matrix environment
- MBA, MS, PharmD, PhD, or other advanced degree (preferred)
- Experience across multiple tumor types or simultaneous launches (preferred)
- Experience in global or franchise roles (preferred)
Benefits
- Retirement Programs
- Paid Time Off
- Health Coverage
- Dental Coverage
- Vision Coverage
- Short-Term Incentive Bonuses
- Equity-Based Awards
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.